Categories: Corporate and commercial, Life Sciences, Pharma, Biotech, Private Equity & Venture Capital, Startup Desk, Deals & Cases
Share:
30 April 2017 
INOFEA AG in Basel, a company developing and commercializing a highly innovative nanotechnology platform to shield sensitive enzymes, successfully closed a financing round with contributions from returning as well as new private investors. INOFEA is a spin-out from the School of Life Sciences, University of Applied Sciences and Arts, Northwestern Switzerland (FHNW).
VISCHER with Dr. Matthias Staehelin (Partner) and Sebastian Flückiger (Associate), both Corporate, advise INOFEA.
Matthias Staehelin
Attorney at Law and Civil Law Notary (BS/BL)
- Partner
- +41 58 211 33 53
- [email protected]